PRESS RELEASE published on 07/24/2026 at 07:00, 2 months 1 day ago Ipsen provides update on Phase III BOLD trial in biliary atresia Ipsen's Phase III BOLD trial for biliary atresia did not meet primary endpoint. Bylvay safety profile confirmed. Insights gained will aid future research and patient care Ipsen Biliary Atresia Phase III BOLD Trial Bylvay Pediatric Liver Transplant
BRIEF published on 07/09/2026 at 07:05, 2 months 16 days ago Positive Phase III Results for Dysport® in the Treatment of Migraine Phase III Dysport Episodic Migraine Chronic Migraine Botulinum Toxin
BRIEF published on 07/09/2026 at 07:05, 2 months 16 days ago Dysport® Achieves Milestone in Migraine Phase III Trials Phase III Trials Dysport Episodic Migraine Chronic Migraine Botulinum Toxin
PRESS RELEASE published on 07/09/2026 at 07:00, 2 months 16 days ago Dysport® is the first botulinum toxin to achieve positive topline Phase III results in both episodic and chronic migraine. Dysport® achieves positive topline Phase III results in both episodic and chronic migraine, marking a significant advancement in migraine treatment Prevention Dysport® Botulinum Toxin Phase III Results Migraine
BRIEF published on 07/06/2026 at 12:02, 2 months 19 days ago BlackRock's stake in IPSEN SA fluctuates at the 5% threshold. Share Capital Voting Rights BlackRock Threshold Crossing Ipsen SA
BRIEF published on 06/29/2026 at 07:05, 2 months 26 days ago Ipsen to Acquire Kartos Therapeutics, Enhancing Hemato-Oncology Portfolio Hemato-oncology Ipsen Acquisition Ruxolitinib Myelofibrosis Navtemadlin
PRESS RELEASE published on 06/29/2026 at 07:00, 2 months 26 days ago Ipsen to acquire Kartos Therapeutics, expanding hemato-oncology late-stage pipeline Ipsen acquires Kartos Therapeutics, adding navtemadlin, a late-stage rare blood cancer asset in Phase III, to expand its Oncology portfolio. Top-line data from Phase III trial expected in 2027 Phase III Ipsen Hemato-oncology Navtemadlin Kartos Therapeutics
BRIEF published on 05/18/2026 at 07:05, 4 months 7 days ago Ipsen Initiates New Share Buy-back Program Share Buy-back Shareholder Value Investment Strategy Employee Share Plans Euronext: IPN
PRESS RELEASE published on 05/18/2026 at 07:00, 4 months 7 days ago Ipsen initiates a new share buy-back program Ipsen initiates new share buy-back program to purchase up to 350,000 shares, representing 0.42% of share capital. Program authorized by Annual General Meeting Share Buy-back Program Investment AGM Ipsen Employee Share-allocation
BRIEF published on 04/03/2026 at 07:05, 5 months 22 days ago Beech Tree Gains Exemption from Public Tender Offer for Ipsen Financial Markets Authority Ipsen Beech Tree Alasol Foundation Tender Offer Exemption
Published on 09/25/2026 at 17:30, 22 minutes ago Goldcliff Announces Unit and Flow Through "LIFE" Offerings
Published on 09/25/2026 at 15:00, 2 hours 52 minutes ago HM Exploration Provides Program Update for the Lewis Pilley's Project
Published on 09/25/2026 at 14:00, 3 hours 52 minutes ago Karbon-X (OTCQB:KARX) to Present Global Growth Strategy and Showcase SkyXero at 26th MK-Equity Investment Conference in Munich
Published on 09/25/2026 at 13:00, 4 hours 52 minutes ago Core Silver Announces Grant of Stock Options
Published on 09/25/2026 at 13:00, 4 hours 52 minutes ago American Hotel Income Properties REIT LP Announces Corporate Update
Published on 09/25/2026 at 17:30, 22 minutes ago GEVELOT S.A.: Weekly declaration of share buybacks – 09/25/2026 (French only)
Published on 09/25/2026 at 17:17, 35 minutes ago Amendments to the Bond Terms and Conditions Have Been Implemented
Published on 09/25/2026 at 16:33, 1 hour 18 minutes ago Genel Energy PLC: Successful tap issue of bonds
Published on 09/25/2026 at 16:10, 1 hour 42 minutes ago Amundi Index Solutions: NOTICE TO SHAREHOLDERS
Published on 09/25/2026 at 16:00, 1 hour 52 minutes ago Deutsche Beteiligungs AG: Balance sheet investment in Vected; hidden champion in optronics for defence and security
Published on 09/24/2026 at 18:00, 23 hours 52 minutes ago GUILLEMOT CORPORATION: Availability of the interim financial report to June 30, 2026
Published on 09/24/2026 at 18:00, 23 hours 52 minutes ago GUILLEMOT CORPORATION: 2026 CONSOLIDATED INTERIM RESULTS
Published on 09/24/2026 at 17:45, 1 day ago Cegedim first-half 2026 results: profitability continues to improve
